Novacyt ALNOV
Graham Mullis, CEO of the Novacyt Group, commented:
“Novacyt continues to process COVID-19 tests for current and future demand. We continue to ensure that innovation is at the center of our strategy and that our growing portfolio of COVID-19 tests is available to clients in private and public healthcare facilities to expand existing partnerships and support new partnerships. Throughout the pandemic, the demand for NHS testing has remained a key priority for the company and the award of the contract under the National PHE Microbiology Framework is a testament to our continued commitment.
“We believe that our long-term strategy also supports the growth of Novacyt after COVID-19. In particular, our progress and growth potential in the private sector will not only help us maximize the opportunity for COVID-19 testing, but also ensure that we are well positioned, along with technologies and partners, for sustainable growth. beyond COVID-19. We therefore believe that Novacyt is well placed to continue to develop its business transformation. "
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.
About the Novacyt Group
The Novacyt Group is an international diagnostic company generating a growing portfolio of in vitro and molecular diagnostic tests. Its main strengths lie in the development, marketing, design and manufacture of diagnostic products. The main business units of the Company include the Primerdesign and Lab21 products, providing a wide range of high quality assays and reagents worldwide. The Group directly serves the microbiology, hematology and serology markets as well as its global partners, including large companies.
“Novacyt continues to process COVID-19 tests for current and future demand. We continue to ensure that innovation is at the center of our strategy and that our growing portfolio of COVID-19 tests is available to clients in private and public healthcare facilities to expand existing partnerships and support new partnerships. Throughout the pandemic, the demand for NHS testing has remained a key priority for the company and the award of the contract under the National PHE Microbiology Framework is a testament to our continued commitment.
“We believe that our long-term strategy also supports the growth of Novacyt after COVID-19. In particular, our progress and growth potential in the private sector will not only help us maximize the opportunity for COVID-19 testing, but also ensure that we are well positioned, along with technologies and partners, for sustainable growth. beyond COVID-19. We therefore believe that Novacyt is well placed to continue to develop its business transformation. "
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.
About the Novacyt Group
The Novacyt Group is an international diagnostic company generating a growing portfolio of in vitro and molecular diagnostic tests. Its main strengths lie in the development, marketing, design and manufacture of diagnostic products. The main business units of the Company include the Primerdesign and Lab21 products, providing a wide range of high quality assays and reagents worldwide. The Group directly serves the microbiology, hematology and serology markets as well as its global partners, including large companies.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.